Literature DB >> 22513796

[GATA1-mutation associated leukemia in children with trisomy 21 mosaic].

D Reinhardt1, K Reinhardt, C Neuhoff, A Sander, J-H Klusmann, A Pekrun, A Sauerbrey, A von Stackelberg, C Rössig, U Creutzig, A Kolenova.   

Abstract

Mutations of the hematopoietic transcription factor GATA1 (GATA1s) are pathognomonic in newborn with transient leukemia and children with Down syndrome and myeloid leukemia (ML-DS). Both TL and ML-DS can also occur in children with trisomy 21 mosaic.Between 2002 and 2011, 15 newborns and infants were diagnosed with DS mosaic. 9 of them presented with TL and 8 children suffered from ML-DS; 2 of them with a history of TL. In children without stigmata the special morphology and immunophenotype of blasts triggered the screening for GATA1 mutation and trisomy 21 mosaic.All newborns with TL achieved complete remission (CR). Due to clinical symptoms caused by the leukemic blasts, in 3 children low-dose cytarabine was applied. 1 patient died due to cardiac defect. In all patients GATA 1 s was confirmed. 6 children with ML-DS were initially treated according the AML-BFM protocol. After ML-DS was confirmed, therapy was continued with the intensity reduced schedule according to the ML-DS 2006 protocol. All children are still in CR (follow-up 1.8-7 years, median 2.7 yrs). 2 children with unknown trisomy 21 mosaic were diagnosed as acute megakaryoblastic leukemia (AMKL) and treated according the high risk arm of the AML-BFM 2004 including allogeneic stem cell transplantation in one child). GATA1 mutation was identified retrospectively. Both children are alive in CR.GATA1s associated leukemia has to be excluded in all young children with AMKL (<5 years old) to prevent overtreatment. Treatment with reduced intensity seems sufficient in children trisomy 21 mosaic and ML-DS. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513796     DOI: 10.1055/s-0032-1308988

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  4 in total

1.  Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes.

Authors:  Jasmijn D E de Rooij; Cristyn Branstetter; Jing Ma; Yongjin Li; Michael P Walsh; Jinjun Cheng; Askar Obulkasim; Jinjun Dang; John Easton; Lonneke J Verboon; Heather L Mulder; Martin Zimmermann; Cary Koss; Pankaj Gupta; Michael Edmonson; Michael Rusch; Joshua Yew Suang Lim; Katarina Reinhardt; Martina Pigazzi; Guangchun Song; Allen Eng Juh Yeoh; Lee-Yung Shih; Der-Cherng Liang; Stephanie Halene; Diane S Krause; Jinghui Zhang; James R Downing; Franco Locatelli; Dirk Reinhardt; Marry M van den Heuvel-Eibrink; C Michel Zwaan; Maarten Fornerod; Tanja A Gruber
Journal:  Nat Genet       Date:  2017-01-23       Impact factor: 38.330

2.  Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study.

Authors:  Jasmijn D E de Rooij; Riccardo Masetti; Marry M van den Heuvel-Eibrink; Jean-Michel Cayuela; Jan Trka; Dirk Reinhardt; Mareike Rasche; Edwin Sonneveld; Todd A Alonzo; Maarten Fornerod; Martin Zimmermann; Martina Pigazzi; Rob Pieters; Soheil Meshinchi; C Michel Zwaan; Franco Locatelli
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

3.  Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.

Authors:  Jana Schweitzer; Martin Zimmermann; Mareike Rasche; Christine von Neuhoff; Ursula Creutzig; Michael Dworzak; Dirk Reinhardt; Jan-Henning Klusmann
Journal:  Ann Hematol       Date:  2015-04-28       Impact factor: 3.673

4.  The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm.

Authors:  Samantha O'Hagan Henderson; Anita Glaser; Jochen J Frietsch; Andreas Hochhaus; Inken Hilgendorf
Journal:  Ann Hematol       Date:  2021-09-01       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.